

Lifesciences, UK

Highlights of our experience:

Almirall, S.A.

- The transfer of its respiratory franchise for an initial consideration of USD 875m on completion, and up to USD 1.22bn in development, launch and sales-related milestone payments.

Johnson & Johnson

- The UK aspects of the sale of the Ortho-Clinical Diagnostics business to The Carlyle Group.

PGT Healthcare LLP

- A joint venture created by Proctor & Gamble, on an innovative collaboration agreement with Swisse Wellness Group Pty Limited, Australia's leading 'wellness' brand. The collaboration relates to vitamin, mineral and food supplement products, which will be marketed across a number of territories and was one of the biggest ever licensing deals for an Australian company.

Francis Crick Institute

- The transfer of research activities and associated assets from the Medical Research Council and Cancer Research UK.

Perrigo Company

- The acquisition of Rosemont Pharmaceuticals Ltd for GBP 180m.

University of Glasgow

- All legal matters relevant to the establishment of the Stratified Medicine Scotland Innovation Centre ((SMS-IC), an initiative funded by the Scottish Funding Council.

Great Ormond Street Hospital

- The connection with its high-profile GBP 320m redevelopment.

Takeda Pharmaceutical Company Limited

- The EUR 9.6bn (debt-free cash free) acquisition of Swiss drug company, Nycomed A/S. This was one of the most significant deals to occur in the lifesciences sector, with this acquisition increasing Takeda's footprint and strength in the European market and emerging markets.

AbbVie

- Litigation by Chemistree Homecare regarding refusal to supply claims for specific specialist medicines.

Wellcome Trust

- The first euro-denominated bond issue, which raised EUR 400m for its important medical research work as one of the world's largest charitable foundations.